MarginsXMarginsX
Home › Markets › Health Care › ADAG

Adagene Inc. (ADAG)

ADAG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.60
-6.43% on the day
Market cap
$105.7M
Micro cap
Revenue · 2025
$7.7M
+7332.8% on 2024
Net income · 2025
-$17.6M
-229.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/0001104659-26-038612-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerADAG on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryChina
IPO year2021
SEC CIK0001818838
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$7.7M
Net income-$17.6M
Operating income-$21.4M
Net margin-229.6%
Operating margin-279.5%
Revenue growth+7332.8%
Cash$74.5M
Total assets$78.3M
P/E (computed)Net income was not positive
P/S (computed)13.8×

Warning signs

Cash runway
57.1 months
$74.5M cash at December 31, 2025
Share count, 1 year
+0.6%
2024-12-31 to 2025-12-31 · +9.6% over 3 years
Going-concern doubt
No
20-F filed April 1, 2026
Insider net buying, 12 months
$162K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-01
Cash and burn$74.5M cash; operating cash flow -$3.9M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-04-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers Zhong Tian LLP, Shanghai, ChinaPCAOB Form AP 2026-04-29
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $162K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$7.7M-$17.6M-$15.7M$74.5M$1.8M$7.7M20-F 2026-04-01
FY 2024
2024-12-31
$103K-$33.4M-$29.7M$85.2M$13.3M$103K20-F 2026-04-01
FY 2023
2023-12-31
$18.1M-$18.9M-$28.5M$109.9M$17.7M$18.1M20-F 2026-04-01
FY 2022
2022-12-31
$9.3M-$80.0M-$48.6M$143.8M$17.0M$9.3M20-F 2025-03-24
FY 2021
2021-12-31
$10.2M-$73.2M-$43.4M$174.4M$4.4M$10.2M20-F 2024-03-29
FY 2020
2020-12-31
$701K-$42.4M-$28.5M$75.2M$4.1M$701K20-F 2023-04-28
FY 2019
2019-12-31
$480K-$16.4M-$18.2M$92.5M$1.8M$480K20-F 2022-04-26
FY 2018
2018-12-31
$1.5M-$15.3M-$14.3M$16.1MNo debt tags$1.5M20-F 2021-04-28

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-02
Latest annual report20-F2026-04-01
Latest quarterly / interim
FORM 6-K
6-K2026-11-09

Source: SEC EDGAR submissions feed, 192 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.5%
1 month-30.5%
3 months-54.0%
Year to date-9.5%
1 year-5.0%
From 52-week high-64.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CLLSCellectis S.A.$1.04-11.86%$104.5M
DERMJourney Medical Corporation$3.70-14.55%$104.5M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
ORGOOrganogenesis Holdings Inc.$0.8031-0.86%$104.2M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M
UNCYUnicycive Therapeutics Inc.$3.70+4.23%$103.1M
CUECue Biopharma Inc.$14.10-12.53%$102.4M
OGIOrganigram Global Inc. Common Shares$0.7240-12.62%$102.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier